ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance

Generated record quarterly net revenues of $138.0 million, representing year-over-year growth of 18.4%, and record Rare Disease net revenues of$ 49.2 million, an increase of 102.4% year-over-yearDelivered adjusted non-GAAP EBITDA of $33.2 million, and adjusted non-GAAP diluted earnings per share of$ 1.02Net loss available to common shareholders of $(2.7) million and diluted GAAP loss per share of$ (0.14)On track to close acquisition of Alimera Sciences, Inc. in the third quarter of 2024, adding two durable ...